Related Experiment Video
Updated: Jun 5, 2026
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Rituximab for the treatment of patients with chronic lymphocytic leukemia
Insights
Rituximab, an anti-CD20 monoclonal antibody, significantly improves outcomes for chronic lymphocytic leukemia (CLL) patients. The FCR regimen (fludarabine, cyclophosphamide, rituximab) is highly effective, enhancing survival and response rates in CLL treatment.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Chronic lymphocytic leukemia (CLL) is a B-cell lymphoproliferative disorder characterized by the accumulation of neoplastic lymphocytes.
- These malignant B cells express specific surface markers, including CD20, making it a viable therapeutic target.
- Current CLL treatments aim to eliminate these malignant cells and improve patient survival and quality of life.
Purpose of the Study:
- To evaluate the efficacy of rituximab (anti-CD20 monoclonal antibody) in treating chronic lymphocytic leukemia (CLL).
- To assess the impact of incorporating rituximab into chemotherapy regimens on treatment outcomes.
- To highlight the development of novel monoclonal antibodies targeting CLL cells.
Main Methods:
- Review of clinical trial data, including phase III confirmatory trials.
- Analysis of treatment regimens incorporating rituximab for CLL.
- Immunophenotypic characterization of CLL lymphocytes.
Main Results:
- Rituximab significantly improved complete response rates and progression-free survival in both untreated and relapsed CLL patients.
- The FCR regimen (fludarabine, cyclophosphamide, rituximab) demonstrated superior efficacy and improved overall survival.
- The success of rituximab has stimulated research into new monoclonal antibodies targeting distinct CLL cell surface antigens.
Conclusions:
- Rituximab represents a significant advancement in the treatment of chronic lymphocytic leukemia.
- The FCR regimen is currently the most effective treatment for CLL, offering improved survival benefits.
- Targeting CD20 and other surface antigens holds promise for developing more effective CLL therapies.
Abstract:
Chronic lymphocytic leukemia (CLL) is a lymphoproliferative disorder that originates from antigen-experienced B lymphocytes that do not die and hence accumulate due to external survival signals or undergo apoptosis and are replenished by proliferating precursors. These neoplastic lymphocytes exhibit a characteristic immunophenotype of CD5(+)/CD19(+)/CD20(+)/HLA-DR+/CD23(+)/sIgdim. Thus, the CD20 antigen has been an appealing target for therapy. The introduction of the monoclonal antibody rituximab (anti-CD20) enabled an outstanding advance in CLL treatment. The introduction of this monoclonal antibody into chemotherapy regimens has dramatically improved complete response rates and progression-free survival in patients with both untreated and relapsed CLL. Although only preliminary data from phase III confirmatory trials have been reported, the FCR regimen, which combines fludarabine and cyclophosphamide with rituximab, is currently the most effective treatment regimen for CLL patients, and has also been demonstrated to significantly improve overall survival. The success of rituximab and the identification of other CLL lymphocyte surface antigens have spurred the development of a multitude of monoclonal antibodies targeting distinct proteins and epitopes in an attempt to target CLL cells more effectively.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...